Current and future uses of positron emission tomography in breast cancer imaging

Seminars in Nuclear Medicine

Volumn 34, Issue 3, 2004, Pages 224-240

  Eubank, William B ^a   Mankoff, David A ^b  

^a Puget Sound VA Health Care System   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; TAMOXIFEN; TRACER;

ACCURACY; AXILLA; AXILLARY LYMPH NODE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; GLUCOSE METABOLISM; HUMAN; IMAGE ANALYSIS; IMAGING; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; METASTASIS; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; SENSITIVITY ANALYSIS; SENTINEL LYMPH NODE; SYMPTOM; TREATMENT OUTCOME; WHOLE BODY RADIATION;

EID: 3042806329     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semnuclmed.2004.03.007     Document Type: Article

References (129)

1. Greenlee R.T., Murray T., Bolden S., et al. Cancer Statistics, 2000. CA Cancer J Clin. 50:2000;7-33
2. Hortobagyi G.N. Developments in chemotherapy of breast cancer. Cancer. 88:(suppl 12):2000;3073-3079
3. Feldman L.D., Hortobagyi G.N., Buzdar A.U., et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 46:1986;2578-2581
4. Machiavelli M.R., Romero A.O., Pérez J.E., et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am. 4:1998;125-131
5. Hortobagyi G.N. Salvage chemotherapy for metastatic breast cancer. Semin Hematol. 24:1987;56-61
6. Honig S.H., Swain S.M. Hormonal manipulation in the adjuvant treatment of breast cancer. DeVita V.T., Hellman S., Rosenberg S.A. Important Advances in Oncology. 1993;103-123 JB Lippincott, Philadelphia
7. Wakeling A.E., Nicholson R.I., Gee J.M. Prospects for combining hormonal and nonhormonal growth factor inhibition. Clin Cancer Res. 7:(12 Suppl):2001;4350s-4355s. discussion 4411s-4412s
8. Husband J.E. Monitoring tumor response. Eur Radiol. 6:1996;775-785
9. Tannock I.F., Hill R.P. The Basic Science of Oncology. 1992;McGraw-Hill, New York
10. Wahl R.L., Cody R.L., Hutchins G.D., et al. Primary and metastatic breast carcinoma initial clinical evaluation with PET with radiolabeled glucose antigen 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 179:1991;765-770
11. Nieweg O.E., Kim E.E., Wong W.H., et al. Positron emission tomography with [fluorine-18]-deoxyglucose in the detection and staging of breast cancer. Cancer. 71:1993;3920-3925
12. 18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol. 21:1995;280-283
13. Tse N.Y., Hoh C.K., Hawkins R.A., et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg. 216:1992;27-34
14. Adler L.P., Crowe J.P., Al-Kaisi N.K., et al. Evaluation of breast masses and axillary lymph nodes with [F-18]-2-deoxy-2-fluoro-D-glucose PET. Radiology. 187:1993;743-750
15. Hoh C.K., Hawkins R.A., Glaspy J.A., et al. Cancer detection with whole-body PET using 2-[F-18]-fluoro-2-deoxy-D-glucose. J Comput Assist Tomog. 17:1993;582-589
16. Avril N., Dose J., Janicke F., et al. Metabolic characterization of breast tumors with positron emission tomography using [F-18]-fluorodeoxyglucose. J Clin Oncol. 14:1996;1848-1857
17. Avril N., Rose C.A., Schelling M., et al. Breast imaging with positron emission tomography and [fluorine-18]-fluorodeoxyglucose use and limitations. J Clin Oncol. 18:2000;3495-3502
18. Schirrmeister H., Kuhn T., Guhlmann A., et al. [F-18]-2-deoxy-2-fluoro-D- glucose PET in the preoperative staging of breast cancer Comparison with the standard staging procedures. Eur J Nucl Med. 28:2001;351-358
19. 18F]-FDG positron emission tomography in primary breast cancer Clinical relevance and practicability. Eur J Nucl Med. 23:1996;618-623
20. Parker S.H., Jobe W.E. Large-core breast biopsy offers reliable diagnosis. Diagnostic Imaging. 12:1990;90-97
21. Orel S.G., Schnall M.D., Powell C.M., et al. Staging of suspected breast cancer Effect of MR imaging and MR-guided biopsy. Radiology. 196:1995;115-122
22. Weinberg I., Majewski S., Weisenberger A., et al. Preliminary results for positron emission mammography Real-time functional breast imaging in a conventional mammography gantry. Eur J Nucl Med. 23:1996;804-806
23. Murthy K., Aznar M., Thompson C.J., et al. Results of preliminary clinical trials of the positron emission mammography system PEM-I A dedicated breast imaging system producing glucose metabolic images using FDG. J Nucl Med. 41:2000;1851-1858
24. Murthy K., Aznar M., Bergman A.M., et al. Positron emission mammographic instrument Initial results. Radiology. 215:2000;280-285
25. Mankoff D.A., Dunnwald L.K., Kinahan P.E. Are we ready for dedicated breast imaging approaches? J Nucl Med. 44:2003;594-595. (invited commentary)
26. 18F]-fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer a preliminary observation. Eur J Nucl Med. 25:1998;1429-1434
27. 18F]fluoro-D-glucose. Cancer. 82:1998;2227-2234
28. 18F-FDG-PET Hhistologic and immunohistochemical tissue analysis. J Nucl Med. 42:2001;9-16
29. 18F]-fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 20:2002;379-387
30. Mankoff D.A., Dunnwald L.K., Gralow J.R., et al. Blood flow and metabolism in locally advanced breast cancer (LABC) Relationship to response to therapy. J Nucl Med. 43:2002;500-509
31. Buck A., Schirrmeister H., Kuhn T., et al. FDG uptake in breast cancer correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 29:2002;1317-1323
32. Dehdashti F., Mortimer J.E., Siegel B.A., et al. Positron tomographic assessment of estrogen receptors in breast cancer Comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 36:1995;1766-1774
33. Crippa F., Agresti R., Seregni E., et al. Prospective evaluation of [fluorine-18]-FDG-PET in presurgical staging of the axilla in breast cancer. J Nucl Med. 39:1998;4-8
34. Hockenberry D. Defining apoptosis. Am J Pathol. 146:1995;16-19
35. Mathapala S.P., Rempel A., Pederson P.L. Aberrant glycolytic metabolism of cancer cells A remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase. J Bioenerg Biomembr. 29:1997;339-343
36. Brand K. Aerobic glycosis by proliferating cells Protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr. 29:1997;335-364
37. L prevents the initial disease in mitochondrial membrane potential and subsequent reactive oxygen species production during tumor necrosis factor alpha-induced apoptosis. MolCell Biol. 20:2000;5680-5689
38. West K.A., Castillo S.S., Dennis P.A. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat. 6:2002;234-248
39. Mankoff D.A., Dehdashti F., Shields A.F. Characterizing tumors using metabolic imaging PET imaging of cellular proliferation and steroid receptors. Neoplasia. 2:2000;71-88
40. 18F]- fluoromisonidazole A pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys. 36:1996;417-428
41. Adler L.P., Faulhaber P.F., Schnur K.C., et al. Axillary lymph node metastases Screening with [F-18]-2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology. 203:1997;323-327
42. Utech C.I., Young C.S., Winter P.F. Prospective evaluation of [fluorine-18]-fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med. 23:1996;1588-1593
43. Avril N., Dose J., Janicke F., et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst. 88:1996;1204-1209
44. Smith I.C., Ogston K.N., Whitford P., et al. Staging of the axilla in breast cancer accurate in vivo assessment using positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Ann Surg. 228:1998;220-227
45. Greco M., Crippa F., Agresti R., et al. Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography Clinical evaluation and alternative management. J Natl Cancer Inst. 93:2001;630-635
46. Wahl R.L., Siegel B.A., Coleman R.E., et al. Prospective multi-center study of axillary nodal staging with FDG positron emission tomography in breast cancer. J Nucl Med. 44:2003;77P. (abstract)
47. Silverstein M.J., Gierson E.D., Waisman J.R., et al. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer. 73:1994;664-667
48. Yeatman T.J., Cox C.E. The significance of breast cancer lymph node micrometastases. Surg Oncol Clin N Am. 8:1999;481-496
49. Albertini J.J., Lyman G.H., Cox C., et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 276:1996;1818-1822
50. Barranger E., Grahek D., Antoine M., et al. Evaluation of fluorodeoxyglucose positron emission tomography in the detection of axillary lymph node metastases in patients with early-stage breast cancer. Ann Surg Oncol. 10:2003;622-627
51. van der Hoeven J.J., Hoekstra O.S., Comans E.F., et al. Determinants of diagnostic performance of [F-18]fluorodeoxyglucose positron emission tomography for axillary staging in breast cancer. Ann Surg. 236:2002;619-624
52. Guller U., Nitzsche E.U., Schirp U., et al. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose not yet! Breast Cancer Res Treat. 71:2002;171-173
53. Yang J.H., Nam S.J., Lee T.S., et al. Comparison of intraoperative frozen section analysis of sentinel node with preoperative positron emission tomography in the diagnosis of axillary lymph node status in breast cancer patients. Jpn J Clin Oncol. 31:2001;1-6
54. Kelemen P.R., Lowe V., Phillips N. Positron emission tomography and sentinel lymph node dissection in breast cancer. Clin Breast Cancer. 3:2002;73-77
55. Wagner J.D., Schauwecker D., Davidson D., et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 17:1999;1508-1515
56. Wojcik C., Yahonda A., McFarlane D., et al. Economic analysis of sentinel-node surgery versus preoperative FDG-PET in the management of patients with intermediate thickness cutaneous melanomas. J Nucl Med. 38:1997;34P. (abstract)
57. Eubank W.B., Mankoff D.A., Schmiedl U.P., et al. Imaging of oncologic patients Benefit of combined CT and [F-18]-fluorodeoxyglucose positron emission tomography scan interpretation in the diagnosis of malignancy. AJR. 171:1998;1103-1110
58. Katz A., Strom E.A., Buchholz T.A., et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy Implications for postoperative irradiation. J Clin Oncol. 18:2000;2817-2827
59. Hathaway P.B., Mankoff D.A., Maravilla K.R., et al. The value of combined FDG-PET and magnetic resonance imaging in the evaluation of suspected recurrent local-regional breast cancer preliminary experience. Radiology. 210:1998;807-814
60. Ahmad A., Barrington S., Maisey M., et al. Use of positron emission tomography in evaluation of brachial plexopathy in breast cancer patients. Br J Cancer. 79:1999;478-482
61. Donegan W.L. The influence of untreated internal mammary metastases upon the course of mammary cancer. Cancer. 39:1977;533-538
62. Cody H.S. 3rd, Urban J.A. Internal mammary node status A major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol. 2:1995;32-37
63. Sugg S.L., Ferguson D.J., Posner M.C., et al. Should internal mammary nodes be sampled in the sentinel lymph node era? Ann Surg Oncol. 7:2000;188-192
64. Bellon JR, Gralow JR, Livingston RB, et al. Evaluation of the internal mammary (IM) lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clinical Oncol (in press)
65. Bernstein V., Jones A., Mankoff D.A., et al. Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission (FDG-PET) in medial hemisphere breast cancer. J Nucl Med. 41:2000;289P. (abstract)
66. Vansteenkiste J.F., Stroobants S.G., De Leyn P.R., et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan A prospective study on 690 lymph node stations from 68 patients. J Clin Oncol. 16:1998;2142-2149
67. Scott W.J., Gobar L.S., Terry J.D., et al. Mediastinal lymph node staging of non-small-cell lung cancer A prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg. 111:1996;642-648
68. 18Fluorodeoxyglucose positron emission tomography to detect mediastinal or internal mammary metastases in breast cancer. J Clin Oncol. 19:2001;3516-3523
69. Moon D.H., Maddahi J., Silverman D.H.S., et al. Accuracy of whole-body [fluorine-18]-FDG-PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 39:1998;431-435
70. 18fluoro- deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res. 17:1997;1687-1692
71. Lonneux M., Borbath I., Berliere M., et al. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clinical Positron Imaging. 3:2000;45-49
72. Kim T.S., Moon W.K., Lee D.S., et al. Fluorodeoxyglucose positron emission tomography for detection of recurrent or metastatic breast cancer. World J Surg. 25:2001;829-834
73. Siggelkow W., Zimny M., Faridi A., et al. The value of positron emission tomography in the follow-up for breast cancer. Anticancer Res. 23:2003;1859-1867
74. 18F-FDG-PET in the local/regional evaluation of women with breast cancer. Breast Cancer Res Treat. 75:2002;135-146
75. 18F]- Fluorodeoxyglucose positron emission tomography in patients with suspected recurrence of breast cancer. J Cancer Res Clin Oncol. 129:2003;147-153
76. 18F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels a preliminary report. Jpn J Clin Oncol. 32:2002;244-247
77. Gallowitsch H.J., Kresnik E., Gasser J., et al. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma a comparison to conventional imaging. Invest Radiol. 38:2003;250-256
78. Suarez M., Perez-Castejon M.J., Jimenez A., et al. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers. Q J Nucl Med. 46:2002;113-121
79. Eubank W.B., Mankoff D.A., Vesselle H.J., et al. Detection of locoregional and distant recurrences in breast cancer patients by using FDG-PET. Radiographics. 22:2002;5-17
80. 18F-FDG-PET and conventional imaging for predicting outcome in previously treated breast cancer patients. J Nucl Med. 43:2002;325-329
81. Nielsen O.S., Munro A.J., Tannock I.F. Bone metastases pathophysiology and management policy. J Clin Oncol. 9:1991;509-524
82. 18FDG-PET differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol. 16:1998;3375-3379
83. Schirrmeister H., Guhlmann A., Kotzerke J., et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol. 17:1999;2381-2389
84. Schirrmeister H., Glatting G., Hetzel J., et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and [18]F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med. 42:2001;1800-1804
85. 18FDG-PET on staging and managing patients with breast cancer the referring physician's perspective. J Nucl Med. 42:2001;1334-1337
86. Eubank W.B., Mankoff D.A., Bhattacharya M., et al. Impact of [F-18]-Fluorodeoxyglucose PET on defining the extent of disease and management of patients with recurrent or metastatic breast cancer. AJR. 2004;. (in press)
87. Helvie M.A., Joynt L.K., Cody R.L., et al. Locally advanced breast carcinoma accuracy of mammography versus clinical examination in the prediction of residual disease after chemotherapy. Radiology. 198:1996;327-332
88. Wahl R.L., Zasadny K., Helvie M.A., et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography initial evaluation. J Clin Oncol. 11:1993;2101-2111
89. Bassa P., Kim E.E., Inoue T., et al. Evaluation of preoperative chemotherapy using PET with [fluorine-18]-fluorodeoxyglucose in breast cancer. J Nucl Med. 37:1996;931-938
90. Jansson T., Westlin J., Ahlstrom H., et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer a method for early therapy evaluation? J Clin Oncol. 13:1995;1470-1477
91. 18F]-fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 18:2000;1689-1695
92. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol. 18:2000;1676-1688
93. Jain R.K. Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol. 60:1991;85-100
94. Mankoff D.A., Dunnwald L.K., Gralow J.R., et al. Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med. 44:2003;1806-1814
95. 18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer. 1:2000;156-161
96. Schneider J.A., Divgi C.R., Scott A.M., et al. Flare on bone scintigraphy following taxol chemotherapy for metastatic breast cancer. J Nucl Med. 35:1994;1748-1752
97. Vogel C., Schoenfelder J., Shemano I., et al. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer. J Clin Oncol. 13:1995;1123-1128
98. Stafford S.E., Gralow J.R., Schubert E.K., et al. Use of serial FDG-PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol. 9:2001;913-921
99. Mortimer J.E., Dehdashti F., Siegel B.A., et al. Metabolic flare indicator of hormone responsiveness in advanced breast cancer. J Clin Oncol. 19:2001;2797-2803
100. Tannock I.F. Cell proliferation. Tannock I.F., Hill R.P. The Basic Science of Oncology. 1992;McGraw-Hill, New York
101. Cleaver J.E. Thymidine metabolism and cell kinetics. Frontiers Biol. 6:1967;43-100
102. Livingston R.B., Hart J.S. The clinical applications of cell kinetics in cancer therapy. Annu Rev Toxicol. 17:1977;529-543
103. Shields A.F., Mankoff D.A., Link J.M., et al. [Carbon-11]-thymidine and FDG to measure therapy response. J Nucl Med. 39:1998;1757-1762
104. Shields A.J., Grierson J., Dohmen B.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med. 4:1998;1334-1336
105. Grierson J.R., Shields A.F. Radiosynthesis of 3′-deoxy-3′- [(18)F]fluorothymidine [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 27:2000;143-156
106. Vesselle H., Grierson J., Muzi M., et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans Correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 8:2002;3315-3323
107. Pio B.S., Park C.K., Satyamurthy, et al. PET with fluoro-L-thymidine allows early prediction of breast cancer response to chemotherapy. J Nucl Med. 44:2003;76P. (abstract)
108. Sutherland R.M. Tumor hypoxia and gene expression - implications for malignant progression and therapy. Acta Oncol. 37:1998;567-574
109. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev. 13:1994;139-168
110. Vaupel P., Hockel M. Oxygenation status of breast cancer the Mainz experience. Vaupel P., Kelleher. Tumor Hypoxia. Stuttgart, Wissenschaftliche Veragsgesellschaft mbH. 1999;1-11
111. Clavo A.C., Wahl R.L. Effects of hypoxia on the uptake of tritiated thymidine, L-leucine, L-methionine and FDG in cultured cancer cells. J Nucl Med. 37:1996;502-506
112. Rajendran J.G., Mankoff D.A., O'Sullivan F., et al. Hypoxia and glucose metabolism in malignant tumors evaluation by FMISO and FDG-PET imaging. Clin Cancer Res. 10:2004;2245-2252
113. Rasey J.S., Koh W., Grierson J.R., et al. Radiolabeled fluoromisonidazole as an imaging agent for tumor hypoxia. Int J Radiat Oncol Biol Phys. 17:1989;985-991
114. Rajendran J.G., Krohn K.A. Imaging tumor hypoxia. Bailey D.L., Townsend D.W., Valk P.E., Maisey M.N. Positron Emission Tomography Principles and Practice. 2002;689-696 Springer Verlag, London
115. McGuire W., Horwitz K. Predicting response to endocrine therapy in human breast cancer a hypothesis. Science. 189:1975;726-727
116. Sledge G.J., McGuire W. Steroid hormone receptors in human breast cancer. Adv Cancer Res. 38:1983;61-75
117. Hull D.F. 3rd, Clark G.M., Osborne C.K., et al. Multiple estrogen receptor assays in human breast cancer. Cancer Res. 43:1983;413-416
118. Reiner A., Neumeister B., Spona J., et al. Immunocytochemical localization of estrogen and progesterone receptor and prognosis in human primary breast cancer. Cancer Res. 50:1990;7057-7061
119. Katzenellenbogen J.A., Welch M.J., Dehdashti F. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 17:1997;1573-1576
120. 18F-labeled difluoroestrodiols preparation and preclinical evaluation as estrogen receptor-binding radiopharmaeceuticals. Steroids. 67:2002;765-775
121. Kiesewetter D.O., Kilbourn M.R., Landvatter S.W., et al. Preparation of four fluorine-18-labeled estrogens and their selective uptakes in target tissue of immature rats. J Nucl Med. 25:1984;1212-1221
122. Mintun M.A., Welch M.J., Siegel B.A., et al. Breast cancer PET imaging of estrogen receptors. Radiology. 169:1988;45-48
123. 18F]Fluoroestradiol (FES) in patients with estrogen receptor positive (ER+) breast cancer. J Nucl Med. 43:2002;287P. (abstr)
124. McGuire A.H., Dehdashti F., Siegel B.A., et al. Positron tomographic assessment of 16alpha-[F-18]-fluoro-17beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med. 32:1991;1526-1531
125. 18F]- fluoroestradiol radiation dosimetry in human PET studies. J Nucl Med. 42:2001;679-684
126. Mankoff D.A., Peterson L.M., Tewson T.J., et al. Non-invasive PET imaging of ER expression in breast cancer sex steroid binding protein (SBP or SHBG) interaction and ER expression heterogeneity. Proc AACR. 42:2001;6. (abstract)
127. Campbell F.C., Blamey R.W., Elston C.W., et al. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet. 1:1981;1317-1319
128. Dehdashti F., Flanagan F.L., Mortimer J.E., et al. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy. Eur J Nucl Med. 26:1999;51-56
129. Mankoff D.A., Peterson L.M., Stekhova S., et al. Uptake of [F-18]-Fluoroestradiol (FES) predicts response of recurrent or metastatic breast cancer to hormonal therapy. J Nucl Med. 44:2003;126P. (abstr)